Magendra Thakur, MD
Pulmonary Disease · Massena, NYNPI 1427074343
Payments from drug & device makers
Across 287 payments — averaging $211.30 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$57K
- AstraZeneca$986
- Boehringer Ingelheim$566
- Novo Nordisk$431
- Johnson & Johnson$375
- Sanofi$326
- plus $829 from 15 others
What the payments were for
- Speaking & faculty fees$54,30090%
- Travel & lodging$1790%
- Food & beverage$5,95010%
- Education$2140%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 161 | $57,130 |
| AstraZeneca | 42 | $986 |
| Boehringer Ingelheim | 23 | $566 |
| Novo Nordisk | 10 | $431 |
| Johnson & Johnson | 10 | $375 |
| Sanofi | 7 | $326 |
| Harmony Biosciences LLC | 3 | $142 |
| Philips North America LLC | 8 | $122 |
| Lilly USA, LLC | 3 | $105 |
| Jazz Pharmaceuticals Inc. | 3 | $102 |
| Pulmonx Corporation | 1 | $83 |
| CSL Behring | 3 | $68 |
| Merck | 4 | $57 |
| Sunovion Pharmaceuticals Inc. | 2 | $32 |
| Genentech USA, Inc. | 1 | $20 |
| Grifols USA, LLC | 1 | $19 |
| Sanofi-aventis U.S. LLC | 1 | $18 |
| Insmed, Inc. | 1 | $16 |
| Mallinckrodt Enterprises LLC | 1 | $15 |
| Circassia Inc. | 1 | $15 |
| Amarin Pharma, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- TRELEGY ELLIPTA$25,919
- ANORO ELLIPTA$1,200
- FARXIGA$329
- INVOKANA$242
- SYMBICORT$219
- FASENRA$219
- DUPIXENT$125
- ANORO$125
- Xultophy 100/3.6$124
- AREXVY$123
- RYBELSUS$115
- NUCALA$114
How this compares
$60,643 in reported general payments places this provider in the 90th percentile of 1,115 pulmonary disease providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 1,009 | $1,018,696 |
| Prolastin CAlpha-1-Proteinase Inhibitor | 12 | $129,272 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 92 | $126,063 |
| OzempicSemaglutide | 59 | $113,087 |
| EliquisApixaban | 71 | $105,169 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 123 | $99,066 |
| JardianceEmpagliflozin | 50 | $72,252 |
| MounjaroTirzepatide | 43 | $45,818 |
| Breo ElliptaFluticasone/Vilanterol | 75 | $44,266 |
| Combivent RespimatIpratropium/Albuterol Sulfate | 32 | $40,377 |
| XareltoRivaroxaban | 32 | $37,038 |
| FarxigaDapagliflozin Propanediol | 21 | $35,886 |
| Incruse ElliptaUmeclidinium Bromide | 51 | $26,022 |
| JanumetSitagliptin Phos/Metformin Hcl | 17 | $25,381 |
| SymbicortBudesonide/Formoterol Fumarate | 52 | $24,627 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta, Incruse Ellipta, Arnuity Ellipta | $57,130 | $1,199,8411,283 claims |
| AstraZenecaBreztri Aerosphere, Farxiga, Symbicort, Airsupra, Bevespi Aerosphere | $986 | $217,434200 claims |
| Boehringer IngelheimJardiance, Combivent Respimat, Tradjenta, Spiriva Respimat | $566 | $144,336119 claims |
| Grifols USA, LLCProlastin C | $19 | $129,27212 claims |
| Novo NordiskOzempic | $431 | $113,08759 claims |
| Johnson & JohnsonXarelto, Invokana | $375 | $52,88643 claims |
| Lilly USA, LLCMounjaro | $105 | $45,81843 claims |
| MerckJanumet | $57 | $25,38117 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,115 pulmonary disease providers in New York.
Other pulmonary disease in Massena
- Linda RogersNew York$7.1M
- Maria PadillaNew York$3.6M
- R WhiteRochester$3.1M
- Juan WisniveskyNew York$3M
- Bushra MinaNew York$2.5M
- Robert KanerNew York$2.3M
- Negin HajizadehGreenport$2M
- Doreen Addrizzo-HarrisNew York$1.9M
- Sherif El BayadiSyracuse$1.9M
- Daniel LachantRochester$1.6M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.